HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

When should we use TNF antagonists in children with rheumatic disease?

AuthorsPierre Quartier
JournalJoint bone spine (Joint Bone Spine) Vol. 74 Issue 1 Pg. 1-3 (Jan 2007) ISSN: 1778-7254 [Electronic] France
PMID17174585 (Publication Type: Editorial)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab
  • Etanercept
Topics
  • Adalimumab
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents (therapeutic use)
  • Arthritis, Juvenile (drug therapy)
  • Child
  • Etanercept
  • Humans
  • Immunoglobulin G (therapeutic use)
  • Infliximab
  • Receptors, Tumor Necrosis Factor (therapeutic use)
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: